spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth

CPhI Worldwide

PE overhang to fuel CDMO valuations and expansions, while VC overhang will fuel continued demand for services in spite of adverse global conditions



Frankfurt/Amsterdam, 27th October 2022: New research from the CPHI Annual Report 2022 – launched during CPHI Frankfurt (1-3 November, 2022) – predicts that huge volumes of Venture Capital (VC) and Private Equity (PE) cash reserves will drive significant expansion in demand for CRO and CDMO services in the next two years.

Writing in the CPHI Annual Report, Brian Scanlan of Edgewater Capital says that, “Despite the economic and inflationary uncertainty, CRO and CDMOs are likely to be the chief beneficiaries of the investment capital that has poured into biotech during the last two years – with little slowdown in growth – despite the more challenging market conditions.”

His analysis predicts that CPHI Frankfurt exhibitors, and the wider contract services sector, will continue to see strong demand, as measured by historical standards – particularly as biotechs look to advance more targets. Additionally, the parked PE capital will support strong contract sector valuations and, more significantly, investment in CRO/CDMO infrastructure.

In fact, as of June of 2022, the U.S. private equity capital overhang was about $749 billion[i], with Venture Capital sat on a further $300 million. Significantly, Scanlan states that the current industry-predicted growth rates of 7.2%[ii] for CROs and 8.5% for CDMOs[iii] has failed to account for this parked capital.

Putting pandemic-related factors aside, a significant portion of the heightened demand for CRO/CDMO services has been driven by VC-backed pharma and biopharma companies. Presently, VC-funded biotechs are sitting on 2-3 years of cash reserves and this will ultimately transfer through, in part, to contract services. On top of this, biotech funding that has been raised over the last couple of years and is likely to be deployed relatively soon because these closed-end investment vehicles must be used in deals within 4-5 years”, added Scanlan.

Looking at breakdown of the findings in more detail, smaller and medium CDMOs are forecast to see growth driven by the thousands of new compounds entering development, with larger CDMOs benefiting most from later phase compounds. Scanlan suggested the next few years could be particularly profitable for smaller CROs and CDMOs – whose services and culture closely match those of biotechs – if they invest and begin to scale as their clients advance into later phases.

These findings bode extremely well for partnering at CPHI Frankfurt – where some 50,000 pharma executives are expected – with availability constraints possible if much of this capital is deployed quickly. In fact, the large number of compounds already in pipelines are effectively already “queued up” for further development as public markets swing back and funding levels resume.

The other significant factor driving investment is the ongoing preference for some re-shoring in supply chains, and this is likely be accelerated by recent geopolitical issues – the Russian/Ukraine conflict, EU energy concerns, and U.S.-China tensions - all creating uncertainty about moving vital materials around the globe.

The potential negatives for CDMOs include biotech desires to continue to husband cash in the short term spend, with CFOs more involved in contract services proposals. Already, the average proposal value has started to drop as some biotechs are adding more stage gates to their projects in order to divide them into smaller chunks.

Orhan Caglayan, Brand Director at CPhI Frankfurt: “Our experts have identified some large and, until now, under-reported implications for CROs and CDMOs. Not only is the market very positive for the largest players – which is known – but also for the smaller contract services providers and specialists that rely upon CPHI Frankfurt to deliver new pharma network leads. CPHI is at the heart of pharma and over the next few weeks we expect to see record number of interactions on our online platform and, of course, in person in Frankfurt. With so much paused until now, we are seeing huge demand in terms of the numbers of attendees. Such is the growth that we changed the way we support the industry earlier this year and CPHI is now an ongoing 365 day partnering platform.”

To download a full copy of the CPHI Annual Report– featuring detailed insights from 12 experts and the findings from 400 survey global pharma executives, please visit: https://www.cphionline.com/46/resourcefile/13/19/61/CPHI%20AR%202022%20Master%202-3d.pdf
phone +31 (0)20 708 1637
email cphicustomerservice@ubm.com
web www.cphi.com
email Delhi, India
 
Print this page
Send to a friend
   
spacer
News and Press Releases

The Native Antigen Company Introduces New Range of Influenza Antigens

Oxford, UK, 16 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.
More info >>


White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement